Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updates

Sarepta Therapeutics reported second quarter 2026 financial results on August 5, 2026, alongside a leadership change and several pipeline updates. Michael Severino, MD, was appointed Chief Executive Officer and joined the Board of Directors effective July 28, 2026.¹ Severino has more than 25 years of biopharmaceutical leadership experience, including senior executive roles at AbbVie, Amgen and Merck.¹ Former CEO Doug Ingram has stepped down but will remain in an advisory role at the company through the end of 2026 to help with the transition.¹

On the pipeline, the company said readouts from the MAD cohorts of its ongoing Phase 1/2 studies in DM1 and FSHD remain on track for the second half of 2026.¹ For ELEVIDYS, full enrollment of ENDEAVOR Cohort 8 is expected by year-end 2026, with 12-week data from the full cohort anticipated in the first quarter of 2027.¹ Dosing has begun in INSIGHTT, the first-in-human Phase 1 study of SRP-1005, an investigational siRNA candidate for Huntington's disease.¹

On regulatory matters, the FDA has accepted for review Sarepta's supplemental New Drug Applications seeking to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional approval.¹ The applications draw on confirmatory trial data, real-world evidence, and the therapies' safety records, according to the company.

Sarepta narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion, from a prior range of $1.2-$1.4 billion, and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million from $800.0-$900.0 million.¹

On cash, the company ended the quarter with about $945.0 million in cash, cash equivalents, restricted cash and investments, up roughly $197.0 million from the prior quarter, following another quarter of operating profitability.¹ Sarepta said it is positioned to advance its DM1 and FSHD programs using commercial cash flows while maintaining disciplined capital allocation.¹